Processa Pharmaceutical News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) and Processa Pharmaceuticals (NASDAQ:PCSA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Profitability This table compares Enliven Therapeutics and […]

Processa Pharmaceuticals’ (NASDAQ: PCSA) shares skyrocketed by over 260% from their October lows of $0.18 per share. Shares peaked at $0.65 on November 14th and more recently has consolidated around $0.43. The reason for this surge was not immediately clear given the lack of material  events. However upon digging deeper, we’ve uncovered a very interesting […]

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) – Investment analysts at Oppenheimer decreased their Q1 2023 earnings per share (EPS) estimates for shares of Processa Pharmaceuticals in a research report issued on Monday, April 3rd. Oppenheimer analyst F. Brisebois now anticipates that the company will post earnings of ($0.28) per share for the quarter, down […]

Brokerages predict that Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Rating) will announce earnings of ($0.26) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Processa Pharmaceuticals’ earnings. Processa Pharmaceuticals posted earnings per share of ($0.20) in the same quarter last year, which would indicate a negative year-over-year growth rate of […]

BeyondSpring (NASDAQ:BYSI – Get Rating) and Processa Pharmaceuticals (NASDAQ:PCSA – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations. Valuation & Earnings This table compares BeyondSpring and Processa Pharmaceuticals’ […]